申请人:Takeda Pharmaceutical Company Limited
公开号:EP1498125A1
公开(公告)日:2005-01-19
It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.
本发明旨在提供用于器官或骨髓移植、类风湿性关节炎、自身免疫性疾病、过敏性疾病、缺血性脑细胞损伤、心肌梗塞、慢性肾炎和动脉硬化的移植物抗宿主病和/或排斥反应的预防/治疗方法。上述目的可以通过预防/治疗移植物抗宿主疾病和/或器官或骨髓移植、类风湿性关节炎、自身免疫性疾病、过敏性疾病、缺血性脑细胞损伤、心肌梗塞、慢性肾炎和动脉硬化中的排斥反应来实现,其特征在于含有具有 CCR(CC 趋化因子受体)拮抗作用的特定化合物。